You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

ALLERGAN Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and what generic alternatives to ALLERGAN drugs are available?

ALLERGAN has seventy-one approved drugs.

There are two US patents protecting ALLERGAN drugs.

Summary for ALLERGAN

US Patents:	2
Tradenames:	68
Ingredients:	52
NDAs:	71
Patent Litigation for ALLERGAN:	See patent lawsuits for ALLERGAN
PTAB Cases with ALLERGAN as patent owner:	See PTAB cases with ALLERGAN as patent owner

Drugs and US Patents for ALLERGAN

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	BREVICON 21-DAY	ethinyl estradiol; norethindrone	TABLET;ORAL-21	017566-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Allergan	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-002	Aug 13, 2009	AB	RX	Yes	Yes	8,022,228*PED	⤷ Subscribe			Y	⤷ Subscribe
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-004	Mar 9, 2001		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ALLERGAN

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	OCUFEN	flurbiprofen sodium	SOLUTION/DROPS;OPHTHALMIC	019404-001	Dec 31, 1986	3,755,427	⤷ Subscribe
Allergan	BYSTOLIC	nebivolol hydrochloride	TABLET;ORAL	021742-002	Dec 17, 2007	5,759,580	⤷ Subscribe
Allergan	CRINONE	progesterone	GEL;VAGINAL	020701-002	Jul 31, 1997	5,543,150	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ALLERGAN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Sublingual Tablets	5 mg and 10 mg	➤ Subscribe	2013-08-13
➤ Subscribe	Transdermal System Extended-re	3.9 mg/24 hrs	➤ Subscribe	2008-08-19
➤ Subscribe	Ophthalmic Solution	0.30%	➤ Subscribe	2007-07-19
➤ Subscribe	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg	➤ Subscribe	2011-12-19
➤ Subscribe	Sublingual Tablets	2.5 mg	➤ Subscribe	2017-07-27
➤ Subscribe	Extended-release Capsules	60 mg	➤ Subscribe	2009-03-02
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2008-10-14
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.